Cofactor Genomics Newsroom

About

Cofactor Genomics is on a mission to close the Precision Medicine Gap through Predictive Immune Modeling. Cofactor has leveraged its experience as one of the first CAP-certified, clinical RNA sequencing laboratories to develop new methods that accurately and holistically characterize disease. Instead of searching for isolated, single-analyte biomarkers, Cofactor’s products create multidimensional biomarkers that better capture the complex immune response. Cofactor has spent years pioneerin...

Cofactor Genomics is on a mission to close the Precision Medicine Gap through Predictive Immune Modeling. Cofactor has leveraged its experience as one of the first CAP-certified, clinical RNA sequencing laboratories to develop new methods that accurately and holistically characterize disease. Instead of searching for isolated, single-analyte biomarkers, Cofactor’s products create multidimensional biomarkers that better capture the complex immune response. Cofactor has spent years pioneering the molecular and machine learning tools to build a database of Health Expression Models, now integrated into our multidimensional diagnostics. Cofactor Genomics empowers clinicians to be better informed while making treatment decisions to improve patient outcomes.

Press Contacts

Michelle McAdam, Chronic Communications Inc.
(310) 902-1274

Video

Cofactor's OncoPrism will help patients receive the right treatment, sooner.
View on Vimeo

Resources (Files)

Cofactor Genomics - Executive Summary

Bios

Jarret Glasscock is a geneticist and computational biologist leading the team at Cofactor Genomics, a company pioneering the use of multidimensional RNA models in diagnostics. Dr. Glasscock’s work spans from earliest uses of next-gen RNA-seq data, to the first published cancer genome, and he has been covered in GEN, Wired, and Nature.
Jarret Glasscock, PhD
Founder and CEO
View more >>
Dr. David Messina has spent the last 20 years working in computational biology and genetics. He worked on the Human Genome Project at Washington University in Saint Louis, mapped disease genes at the University of Chicago, and earned his PhD in computational biology in Stockholm, Sweden. As COO at Cofactor Genomics, he oversees daily operations and leads regulatory strategy.
David Messina
Chief Operating Officer at Cofactor Genomics
View more >>
Natalie first joined Cofactor Genomics in 2013, with a PhD in Chemistry from Washington University in St. Louis. Natalie has developed customized experimental solutions for both DNA and RNA applications at Cofactor, as well as launched and supported diagnostic reference standards as a part of Horizon Discovery’s Diagnostics Division. Natalie now supports Cofactor’s clinical collaborations and outreach efforts as the VP of Market Development, with the goal of expanding the utility of Predictive Immune Modeling for cancer biomarker discovery.
Natalie LaFranzo, PhD
Vice President of Market Development
View more >>

Social Accounts